Abivax (AAVXF) Enterprise Value (2021 - 2025)

Abivax has reported Enterprise Value over the past 5 years, most recently at -$626.4 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$626.4 million for Q4 2025, down 286.21% from a year ago — trailing twelve months through Dec 2025 was -$626.4 million (down 286.21% YoY), and the annual figure for FY2025 was -$608.0 million, down 270.09%.
  • Enterprise Value for Q4 2025 was -$626.4 million at Abivax, down from -$162.2 million in the prior quarter.
  • Over the last five years, Enterprise Value for AAVXF hit a ceiling of -$27.5 million in Q4 2022 and a floor of -$626.4 million in Q4 2025.
  • Median Enterprise Value over the past 5 years was -$162.2 million (2024), compared with a mean of -$233.3 million.
  • Biggest five-year swings in Enterprise Value: surged 60.4% in 2022 and later plummeted 921.83% in 2023.
  • Abivax's Enterprise Value stood at -$69.4 million in 2021, then surged by 60.4% to -$27.5 million in 2022, then plummeted by 921.83% to -$281.0 million in 2023, then skyrocketed by 42.27% to -$162.2 million in 2024, then plummeted by 286.21% to -$626.4 million in 2025.
  • The last three reported values for Enterprise Value were -$626.4 million (Q4 2025), -$162.2 million (Q4 2024), and -$281.0 million (Q4 2023) per Business Quant data.